← Leaderboards
Mary Kucek
Ovaryit, Llc
$2,421,979
Attributed
$2,421,979
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,421,979 · 2
By mechanism
R44$2,207,260 · 1
R43$214,719 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Guidelines”
- Mari Ostendorf · University Of Washington$51,931,230
- Joon Sup Lee · Emory University$10,751,414
- Colin Osborne · University Of Texas Med Br Galveston$10,407,745
- Kurt Langenbach · Precision Bioservices, Inc.$8,884,583
- Robert C Alexander · Banner Health$8,197,111
- Deborah J Goff · Dana-Farber Cancer Inst$6,540,771
Research focus
GuidelinesPaperExpenditureGovernmentMaternal MortalityOral ContraceptivesEconomicsElectronic Health RecordFamilyFoundationsHealth Services AccessibilityInterestCommercializationMedicalContraceptive AgentsCaringAdoptionCostCost EffectiveEducationClinical Decision SupportDesignDistrict Of ColumbiaPharmacists
Grant awards (3)
Development and commercialization of support tools to improve safety and efficiency of pharmacist-prescribed contraceptive services$865,931
R44 · FY2025 · HD · contact PI
Development and commercialization of support tools to promote safety and adoption of pharmacist prescribed contraceptive services.$1,341,329
R44 · FY2024 · HD · contact PI
Implementation of support tools to promote safety in the prescribing of oral contraceptives$214,719
R43 · FY2022 · HD · contact PI